Luye Pharma Group (HK.02186), a leading Chinese pharmaceutical conglomerate, has declared that its wholly-owned subsidiary, Luye Hong Kong Limited, has secured an exclusive promotion agreement with two subsidiaries of US-based Moksha8 Pharmaceuticals, Moksha8 Brasil Distribuidora e Representação de Medicamentos Ltda. and Moksha8 Farmacéutica, S. de R.L. de C.V. This strategic partnership pertains to the distribution of Seroquel and Seroquel XR in the burgeoning markets of Brazil and Mexico.
Seroquel, featuring quetiapine fumarate in its immediate release (IR) form, and its extended release counterpart, Seroquel XR, are atypical anti-psychotic (AAP) medications endowed with antidepressant qualities. While Seroquel is predominantly indicated for the treatment of schizophrenia and bipolar disorder, Seroquel XR addresses major depressive disorder and generalized anxiety disorder.
Moksha8 Pharmaceuticals is a specialty pharmaceutical enterprise, concentrating on the licensing, marketing, and distribution of innovative and recognized therapeutics, primarily in Brazil and Mexico, which together constitute the largest pharmaceutical markets in Latin America. These two markets accounted for 70% of the region’s pharmaceutical market and exhibited a robust year-on-year growth rate of 9.3% and 8.4% respectively in 2019.
Beyond the Seroquel series, Luye Pharma has an expansive pipeline of central nervous system (CNS) drugs in development. This includes LY03004 for schizophrenia and bipolar disorder, LY03003 for Parkinson’s disease, LY03005 for major depressive disorder, LY03010 for schizophrenia and schizoaffective disorder, LY30410 for mild to moderate Alzheimer’s disease, and LY03012 for chronic pain. The company has indicated that regulatory filings for these products are in progress in China, the US, the European Union (EU), and Japan, with launches anticipated in these territories.
